Last reviewed · How we verify

Fougera Pharmaceuticals Inc. — Portfolio Competitive Intelligence Brief

Fougera Pharmaceuticals Inc. pipeline: 2 marketed, 0 filed, 3 Phase 3, 0 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

2 marketed 0 filed 3 Phase 3 0 Phase 2 0 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

DrugGenericPhaseClassTargetAreaFirst approval
Pandel Cream 0.1% Pandel Cream 0.1% marketed
Fluticasone propionate 0.05% lotion Fluticasone propionate 0.05% lotion marketed Topical corticosteroid (Class III/IV potency) Glucocorticoid receptor Dermatology
Vehicle of 0417 test product Vehicle of 0417 test product phase 3
Tazarotene Cream 0.05% Tazarotene Cream 0.05% phase 3 retinoid retinoic acid receptor Dermatology
Vehicle of 0416 test product Vehicle of 0416 test product phase 3

Therapeutic area mix

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

  1. Actavis Inc. · 1 shared drug class
  2. Ain Shams University · 1 shared drug class
  3. Encube Ethicals Pvt. Ltd. · 1 shared drug class
  4. Galderma R&D · 1 shared drug class
  5. GlaxoSmithKline · 1 shared drug class
  6. Jacob Pontoppidan Thyssen · 1 shared drug class
  7. Kowa Company, Ltd. · 1 shared drug class
  8. Peking Union Medical College Hospital · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Fougera Pharmaceuticals Inc.:

Cite this brief

Drug Landscape (2026). Fougera Pharmaceuticals Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/fougera-pharmaceuticals-inc. Accessed 2026-05-17.

Related